Treatment to make inoperable liver cancer operable

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a combination therapy using FOLFOXIRI and bevacizumab in patients with unresectable liver-only metastatic colorectal cancer. The goal is to convert these patients to a state where surgical resection of liver metastases is possible. The study will assess the conversion rate, disease control, survival, quality of life, and the relationship between early imaging responses and surgical outcomes. A total of 32 eligible patients will be treated and monitored at major cancer centers in Saskatchewan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients, aged between 18 and 70 years with histologically proven adenocarcinoma or poorly differentiated carcinoma of the colon and rectum with unresectable liver-only metastases and no extra-hepatic disease.
* World Health Organization (WHO) performance status of 0-1.
* No previous chemotherapy for advanced disease.
* Adequate functioning of the bone marrow, liver, and kidneys.

Exclusion Criteria:

* Breastfeeding or pregnancy.
* An active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.
* Severe or uncompensated concomitant medical conditions.

Where it's running

• Allan Balir Cancer Center
  Regina, Saskatchewan, Canada Recruiting

Study contacts

• Principal investigator: Shahid Ahmed, MD, PhD — University of Saskatchewan
• Study coordinator: Shahid Ahmed, MD, PhD
• Email: shahid.ahmed@saskcancer.ca
• Phone: 3066552710

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

• Comparing Precem-TcT (with or without bevacizumab) versus trifluridine/tipiracil plus bevacizumab for people with previously treated metastatic colorectal cancer

  This trial will see if Precem-TcT, alone or with bevacizumab, helps people with metastatic colorectal cancer who have already received standard chemotherapy, compared with trifluridine/tipiracil plus bevacizumab.

  Recruiting at 116 sites Phase 3 EMD Serono · San Francisco, California and 115 other locations · NCT07549412

• Evaluating a new treatment for metastatic colorectal cancer

  This study is testing a new drug combined with standard chemotherapy to see if it helps adults with metastatic colorectal cancer feel better and improve their condition.

  Recruiting at 82 sites Phase 2 AbbVie · Duarte, California and 81 other locations · NCT06820463

• Elovie (bevacizumab biosimilar) for metastatic colorectal cancer in Brazil

  This project will see if the biosimilar bevacizumab Elovie works well and is safe for adults in Brazil with unresectable stage IV metastatic colorectal cancer receiving first-line therapy.

  Recruiting at 14 sites Libbs Farmacêutica LTDA · Vitória, Espírito Santo and 13 other locations · NCT06808685

• Combining radioembolization with FTD-TPI and bevacizumab for advanced colorectal cancer

  This study is testing if a new combination of a targeted radiation treatment and two medications can help people with advanced colorectal cancer who haven't responded to other treatments.

  Recruiting Phase 2 UMC Utrecht · Utrecht · NCT06563986

• Combination therapy for metastatic colorectal cancer with BRAF-V600E mutation

  This study is testing a new combination of three drugs to see if it can help people with advanced colorectal cancer that has a specific mutation feel better and live longer after their previous treatments stopped working.

  Recruiting Phase 2 Vall d'Hebron Institute of Oncology · Barcelona · NCT06411600

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.